JPRN-UMIN000005552已完成2 期
A Phase 2 study of pemetrexed and carboplatin for platinum-pretreated patients with non small cell lung cancer - A Phase 2 study of PEM and CBDCA for platinum-pretreated patients with lung cancer
Osaka Prefectural Medical Center for Respiratory and Allergic deseases0 个研究点目标入组 30 人开始时间: 2011年5月4日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Exclusion criterias are as follows 1: Active interstitial pneumonia identified by chest X-ray 2: Uncontrolled massive pleural effusion or cardiac effusion 3: Superior vena cava syndrome 4: Uncontrolled brain metastases 5: Uncontrolled diabetes mellitus, hypertension, hepatic disorder, angina pectoris or previous myocardial infarction within the last 12 months 6: Severe infection 7: Pregnancy or lactation 8: Active concomitant malignancy 9: History of severe allergic reactions to drugs 11: Severe and unstable medical 10morbidities 11: Judgment to attending physician
研究者
相似试验
已完成
不适用
A Phase II Study of Carboplatin and Pemetrexed for elderly patients with Non-Small Cell (Non Squamous cell)Lung CancerSCLC non-squamousJPRN-UMIN000004543Toracic Medical Oncology,Cancer Institute Hospital of JFCR42
已完成
2 期
Phase II study of Pemetrexed and Carboplatin plus Bevacizumab for advanced non-small cell lung cancernon-squamous non-small-cell lung cancerJPRN-UMIN000003680ippon Medical School Hospital26
已完成
2 期
Phase II study of Pemetrexed + Carboplatin as first line therapy for nonsquamous non-small cell lung cancer with interstitial pneumoniaJPRN-UMIN000011325Central Japan Lung Study Group (CJLSG)25
已完成
2 期
A Phase II study of Pemetrexed plus Carboplatin followed by maintenance Pemetrexed in patients with previously untreated stage III/IV or post-operative recurrent non-squamous non-small-cell and lung cancer.on-squamous non-small cell lung cancerJPRN-UMIN000003755Dept. of Respiratory Medicine, Osaka University Hospital40
已完成
2 期
Phase II study of carboplatin and pemetrexed plus bevacizumab after failure of first-line EGFR TKI therapy for non-small-cell lung cancer harboring EGFR mutation.on-squamous Non-small-cell Lung CancerJPRN-UMIN000004731Central Japan Lung Study Group27